Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 5, 2010, Pages 606-609

  Tiraboschi, Juan Manuel ^a   Niubo, Jordi ^a   Curto, Jordi ^a   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

CNS; CSF; HIV; levels; maraviroc

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DIDANOSINE; MARAVIROC; NEVIRAPINE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, LIQUID; CYCLOHEXANES; DIDANOSINE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; TANDEM MASS SPECTROMETRY; TRIAZOLES; VIRAL LOAD;

EID: 78650199767     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ef70fe     Document Type: Article

References (21)

1. Letendre S, Ellis R, Everall I, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2009;17:46-56.
2. Letendre S. Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nevous system. Arch Neurol. 2008;65:65-70.
3. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis. 2005;41:1787-1793.
4. Marra C, Zhao Y, Clifford D, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-1366.
5. Zhou, Xiao-Jian, Havlir, Diane V et al. Plasma population pharmacoki-netics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS. 2000; 14:2869-2876.
6. McArthur J, Haughey N, Gartner S, et al. Human Immunodeficiency virus-associated dementia: an envolving disease. J NeuroVirol. 2003;9: 205-221.
7. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis. 1999;180:862-864.
8. Yilmaz A, Izadkhashti A, Richard W, et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected patients. AIDS Res Hum Retroviruses. 2009;25:457-461.
9. Capparelli EV, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS. 2005;19:949-952.
10. Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009;23:83-87.
11. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56-63.
12. Antinori A, Federico C, Giancola M, et al. Efficacy of cerebrospinal fluid (CSF)- penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of the phenotypic resistance in CSF and plasma Clin Infect Dis. 2005;41:1787-1793.
13. Yilmaz A, Watson V, Else L, et al. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS. 2009;23:2537-2540.
14. Yilmaz A, Gisslén M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One. 2009:4(9):e6877.
15. European Public Assessment Report (EPAR). http://www.emea. europa.eu/humandocs/PDFs/EPAR/celsentri/emea-combined-h811es.pdf. Accessed August 9, 2010.
16. Lee MS, Kerns EH. LC/MS applications in drug development. Mass Spectrom Rev. 1999;18:187-279.
17. Albright AV, Shieh JT, Itoh T, et al. Microglia express CCR5, CXR4, and CCR3, but of these CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol. 1999;73: 205-213.
18. Walker DK, Bowers S, Mitchell R, et al. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica. 2008;38:1330-1339.
19. Letendre S, McCutcham J, Childers M, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56:416-423.
20. Groothuis D, Levy R. The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol. 1997;3:387-400.
21. Clifford D. HIV-Associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2008;16:94-98.